Beyond Bioethics: Toward a New Biopolitics
By Daniel Bojar,
The Biologist [review of the book edited by CGS' Osagie K Obasogie and Marcy Darnovsky]
| 09. 06. 2018
The dramatic pace of scientific discoveries in recent decades has not only led to remarkable improvements in domains such as healthcare or forensics, but has also posed new questions and challenges to society. How do we deal with privacy in an age of commercialised genome sequencing? How do we decide to incorporate concepts of race, gender and class into our restructured healthcare system? These thorny issues and many more are tackled in Beyond Bioethics.
The book itself is a collection of dozens of essays by bioethicists, activists and thinkers from a range of disciplines, collected and curated by Osagie Obasogie and Marcy Darnovsky. Grouping these essays into thematic categories, the imposing bioethical problems of our age are investigated one by one. While the negative outlook provided by many essayists may sometimes seem overwhelming, the diversity of opinions and approaches does justice to the importance of topics such as surrogate pregnancies, negligence of underserved segments of the population, or the finicky subject of who is testing the drugs of the future in clinical trials.
In fact, as the editors of the...
Related Articles
By Rob Stein, NPR [cites CGS' Katie Hasson] | 08.06.2025
A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies.
His work was reviled as reckless and unethical because, among other reasons, gene-editing was so new...
By John H. Evans, Craig Callender, Neal K. Devaraj, Farren J. Isaacs, and Gregory E. Kaebnick, Issues in Science and Technology | 07.04.2025
The controversy around a ban on “mirror life” should lead to a more nuanced public conversation about how to manage the benefits and risks of precursor biotechnologies.
About five years ago, the five of us formed a discussion group to...
By Geoffrey A. Fowler, The Washington Post | 07.17.2025
Nearly 2 million people protected their privacy by deleting their DNA from 23andMe after it declared bankruptcy in March. Now it’s back with the same person in charge — and I still don’t trust it.
Nor do the attorneys general...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...